EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero?

Benjamin Reardon iD, Leonardo Pasalic, Emmanuel J Favaloro iD

Biomolecules · 05.07.2025 · 15 (7) · 967

DOI: 10.3390/biom15070967 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 05.07.2025. Verfasst von Benjamin Reardon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Joint Medical Program, School of Medicine and Public Health, University of Newcastle, Callaghan, NSW 2145, Australia. Hauptthemen laut MEDLINE: Deamino Arginine Vasopressin, Hemostatics. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a synthetic analogue of vasopressin, desmopressin or DDAVP has well established hemostatic properties. We present a review of DDAVP and summarize the clinical and laboratory evidence for its use in hemophilia A, von Willebrand disease (VWD), platelet function disorders, uremia, liver cirrhosis, and pregnancy, followed by illustrative examples of its broad efficacy from our local practice. In brief, DDAVP acts to release von Willebrand factor (VWF) and factor VIII from endogenously stored reserves, thereby correcting plasma deficiencies present in mild to moderately affected patients with hemophilia A and VWD. Thus, DDAVP represents a non-transfusional therapy for these disorders. Typically, a trial of DDAVP is arranged to assess individual responsiveness before employing DDAVP clinically, since there is individual variation in responsiveness. Thereafter, DDAVP can be utilized in responsive patients for clinical use and provides a factor replacement sparing strategy in these patients for some clinical situations. Nevertheless, DDAVP is best applied as a factor replacement sparing strategy, especially for minor procedures or short-term use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Deamino Arginine VasopressinHemostaticsHumansPregnancyvon Willebrand DiseasesHemophilia AFemale

Stichwörter der Autor:innen

DDAVPdesmopressinhemophiliahemostasisvon Willebrand disease

Substanzen

Deamino Arginine VasopressinHemostatics

Autor:innen und Institutionen

  • Joint Medical Program, School of Medicine and Public Health, University of Newcastle, Callaghan, NSW 2145, Australia.
  • Haematology Department, Calvary Mater Hospital Newcastle, Waratah, NSW 2298, Australia.
  • Haematology Department, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW 2145, Australia.
  • Westmead Clinical School, University of Sydney, Westmead, NSW 2145, Australia.
  • Sydney Centres for Thrombosis and Haemostasis, Research and Education Network (REN) and Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, NSW 2145, Australia.
  • School of Dentistry and Medical Sciences, Faculty of Science and Health, Charles Sturt University, Wagga Wagga, NSW 2650, Australia.

ORCID-Profile: Benjamin Reardon, Emmanuel J Favaloro

Zitieren

APA

Reardon, B., Pasalic, L., & Favaloro, E. J. (2025). A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero?. Biomolecules, 15(7), 967. https://doi.org/10.3390/biom15070967

Vancouver

Reardon B, Pasalic L, Favaloro EJ. A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero?. Biomolecules. 2025;15(7):967. doi:10.3390/biom15070967

BibTeX
@article{Reardon2025,
  author = {Reardon, Benjamin and Pasalic, Leonardo and Favaloro, Emmanuel J},
  title = {A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero?},
  journal = {Biomolecules},
  year = {2025},
  volume = {15},
  number = {7},
  pages = {967},
  doi = {10.3390/biom15070967}
}
Kostenlos starten →